Resumen
The effect of acute hyperglycemia per se on coronary perfusion in humans is undefined. We evaluated the effects of short-term hyperglycemia on myocardial blood flow reserve (MBFR) in healthy nondiabetic volunteers. Twenty-one nondiabetic volunteers (76 % females, mean ± SD, age 48 ± 5 years) had noninvasive MBFR assessment while exposed to pancreatic clamp with somatostatin and replacement glucagon and growth hormone infusions, with frequent interval plasma glucose (PG) monitoring. Insulin was infused at 0.75 mU/kg/min to mimic postprandial plasma insulin concentrations, and glucose was infused to maintain euglycemia (PG 93.9 ± 7.3 mg/dl) followed by hyperglycemia (PG 231.5 ± 18.1 mg/dl). Myocardial contrast echocardiography (MCE) was performed during each glycemic steady state using continuous infusion of Definity at rest and during regadenoson (Lexiscan 5 ml (400 μg) intravenous bolus) infusion to quantify myocardial blood flow (MBF) and determine MBFR. Insulin resistance (IR) was assessed by glucose infusion rate (GIR; mg/kg/min) at euglycemia. Median stress MBF, MBFR, and β reserve were significantly reduced during acute hyperglycemia versus euglycemia (stress MBF 3.9 vs 5.4, P = 0.02; MBFR 2.0 vs 2.7, P < 0.0001; β reserve 1.45 vs 2.4, P = 0.007). Using a median threshold GIR of 5 mg/kg/min, there was a correlation between GIR and hyperglycemic MBFR (r = 0.506, P = 0.019). MBFR, as determined noninvasively by MCE, is significantly decreased during acute hyperglycemia in nondiabetic volunteers, and the magnitude of this reduction is modulated by IR.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 757-768 |
Número de páginas | 12 |
Publicación | Heart and Vessels |
Volumen | 28 |
N.º | 6 |
DOI | |
Estado | Published - nov. 2013 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:Dr Sharon Mulvagh received research grants from Lantheus Medical Imaging and Astellas Pharma Global Inc. She has been a member of the Advisory Board for GE Healthcare. All other authors have no conflicts of interest to disclose.
Funding Information:
This project (clinicalTrial.gov identifier# NCT01021865) was supported by NIH/NCRR CTSA Grant Number NCATS UL1 TR000135 and by the Mayo Foundation, to Dr Sharon L Mulvagh Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Dr. Ananda Basu was supported by the grant DK 85516. Contrast agent (Definity) was provided by Lantheus Medical Imaging (North Billerica, MA). Vasodilator stress drug (Lexiscan) was provided by Astellas Pharma Global Inc.
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't